Bulk Pharmaceutical API Sources for ICATIBANT ACETATE

Bulk Pharmaceutical API Sources for ICATIBANT ACETATE

Vendor	Vendor Homepage	Vendor Sku	API Url
DC Chemicals		DC6314
BOC Sciences		138614-30-9
Molport		MolPort-046-426-381

Icatibant Acetate Bulk API Sourcing Landscape

Last updated: February 19, 2026

Icatibant acetate, a bradykinin B2 receptor antagonist, is primarily utilized in the treatment of hereditary angioedema (HAE). The sourcing of its bulk active pharmaceutical ingredient (API) is concentrated among a limited number of manufacturers, reflecting the niche therapeutic area and stringent quality requirements for injectable drugs. Supply chain stability and regulatory compliance are paramount for pharmaceutical companies requiring consistent and high-purity icatibant acetate.

Key API Manufacturers for Icatibant Acetate

The production of icatibant acetate API is characterized by a specialized manufacturing process, often involving peptide synthesis. Companies with established expertise in complex organic synthesis and peptide chemistry are the primary suppliers.

• Bachem AG: A Swiss-based company is a significant player in peptide manufacturing. Bachem has a history of producing complex APIs and is recognized for its quality standards. Their capabilities include custom synthesis and large-scale production of peptide-based therapeutics.
• Peptanova: This Italian company specializes in the synthesis and production of peptides for pharmaceutical applications. Peptanova offers custom synthesis services and has experience in scaling up peptide production for clinical and commercial supply.
• CPC Scientific: A US-based company, CPC Scientific focuses on custom peptide synthesis and manufacturing. They cater to pharmaceutical and biotechnology companies, providing peptides for research and development, as well as commercial manufacturing.
• Other Potential Suppliers: While specific public disclosures are limited, other custom synthesis organizations (CSOs) and contract development and manufacturing organizations (CDMOs) with peptide synthesis expertise may also produce icatibant acetate API, particularly on a contract basis for specific clients. These could include companies such as Lonza or other specialized chemical manufacturers.

Regulatory and Quality Considerations

The production of icatibant acetate API must adhere to strict Good Manufacturing Practice (GMP) guidelines. Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require comprehensive documentation and rigorous quality control throughout the manufacturing process.

• GMP Compliance: All manufacturing facilities must be GMP-certified by relevant health authorities. This includes adherence to standards for facility design, equipment, personnel training, and documentation.
• Impurity Profiling: Detailed impurity profiling is critical for peptide APIs like icatibant acetate. Manufacturers must identify, quantify, and control all process-related impurities and degradation products to ensure patient safety.
• Analytical Methods: Validated analytical methods, such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), are essential for verifying the identity, purity, and potency of the API.
• Stability Studies: Comprehensive stability studies are required to determine the shelf-life of the API under various storage conditions, ensuring its quality over time.
• Drug Master Files (DMFs): API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control measures. Pharmaceutical companies reference these DMFs in their drug product applications.

Market Dynamics and Supply Chain Factors

The market for icatibant acetate API is influenced by several factors:

• Niche Therapeutic Area: Hereditary angioedema affects a relatively small patient population, leading to a smaller overall demand for icatibant acetate compared to blockbuster drugs. This can result in a more concentrated supplier base.
• Complexity of Synthesis: Peptide synthesis is a complex and resource-intensive process, requiring specialized expertise and equipment. This limits the number of companies capable of producing high-quality icatibant acetate API at commercial scale.
• Patent Landscape: The patent status of icatibant itself and its manufacturing processes can influence market entry and competition among API suppliers. Exclusivity periods for innovator products can protect market share.
• Geopolitical Stability: For pharmaceutical supply chains, geopolitical stability in regions where API manufacturing is concentrated is a key consideration. Disruptions can impact availability and pricing.
• Lead Times: Due to the specialized nature of production, lead times for bulk icatibant acetate API can be significant. Pharmaceutical companies must carefully manage their inventory and procurement strategies.
• Pricing: Pricing for peptide APIs is typically higher than for small molecule drugs due to the complexity and cost of manufacturing. Price negotiations are influenced by order volume, contract duration, and supplier relationships.

Comparison of Potential API Suppliers

While direct comparative data on all icatibant acetate API suppliers is not publicly available, general capabilities and industry standing can be inferred.

Manufacturer	Primary Expertise	Scale of Operation	Regulatory Track Record	Geographic Location
Bachem AG	Peptide Synthesis	Large-scale	Extensive	Switzerland
Peptanova	Peptide Synthesis	Medium to Large-scale	Established	Italy
CPC Scientific	Custom Peptide Synthesis	Medium-scale	Good	USA

Note: "Scale of Operation" refers to the general capacity for peptide API manufacturing. Actual capacity for icatibant acetate specifically may vary.

Supply Chain Risk Mitigation

Pharmaceutical companies relying on icatibant acetate API must implement robust strategies to mitigate supply chain risks.

• Dual Sourcing: Establishing relationships with at least two qualified API manufacturers can provide redundancy in case of supply disruptions from a single source. This requires thorough qualification of each supplier, including audits and validation of their GMP compliance.
• Supplier Audits: Regular audits of API manufacturers are essential to ensure ongoing compliance with GMP standards and to assess the manufacturer's quality management systems and production capabilities.
• Inventory Management: Maintaining adequate safety stock levels of the API can buffer against unexpected supply interruptions or demand surges. This requires careful forecasting and consideration of lead times.
• Contractual Agreements: Strong contractual agreements with API suppliers are crucial. These agreements should clearly define quality specifications, delivery schedules, pricing, intellectual property rights, and termination clauses.
• Geographic Diversification: Where possible, sourcing from manufacturers located in different geographic regions can reduce exposure to localized political or economic instability.
• Quality Agreements: Establishing detailed Quality Agreements with each API supplier is vital. These agreements outline the responsibilities of both parties regarding quality control, change management, complaint handling, and regulatory compliance.

Future Outlook

The demand for icatibant acetate API is directly tied to the market penetration and patient population of hereditary angioedema treatments. Advances in HAE management, including improved diagnostics and expanded treatment access, could lead to increased demand. Furthermore, any new therapeutic applications identified for icatibant or its derivatives could further influence API sourcing requirements. The ongoing focus on supply chain resilience in the pharmaceutical industry will likely drive continued emphasis on dual sourcing and robust supplier qualification for critical APIs like icatibant acetate.

Key Takeaways

• The bulk API supply for icatibant acetate is concentrated among specialized peptide manufacturers, including Bachem AG, Peptanova, and CPC Scientific.
• Stringent GMP compliance, impurity control, and validated analytical methods are critical for icatibant acetate API production.
• Niche market size and complex synthesis contribute to a specialized supplier landscape.
• Pharmaceutical companies must prioritize dual sourcing, regular supplier audits, and robust inventory management to ensure supply chain security.

Frequently Asked Questions

What are the primary therapeutic uses for icatibant acetate?

Icatibant acetate is primarily used for the acute treatment of attacks in adult patients with hereditary angioedema (HAE).

What are the main challenges in sourcing icatibant acetate API?

Challenges include the limited number of specialized peptide manufacturers, the complexity and cost of peptide synthesis, and the stringent regulatory requirements for API quality and compliance.

How can pharmaceutical companies ensure the quality of icatibant acetate API from suppliers?

Quality assurance involves rigorous supplier qualification, regular GMP audits, validation of analytical methods, review of stability data, and the establishment of detailed Quality Agreements.

Does the patent status of icatibant acetate affect API sourcing?

Yes, the patent status of icatibant and its manufacturing processes can influence market exclusivity for innovator products, potentially impacting the competitive landscape for generic API manufacturers.

What is the typical lead time for sourcing bulk icatibant acetate API?

Lead times for specialized peptide APIs can be substantial, often ranging from several months to over a year, depending on the supplier's production schedule, order volume, and manufacturing complexity.

Citations

[1] Bachem AG. (n.d.). Peptide Manufacturing. Retrieved from https://www.bachem.com/ [2] Peptanova. (n.d.). Peptide Synthesis. Retrieved from https://www.peptanova.com/ [3] CPC Scientific. (n.d.). Custom Peptide Synthesis. Retrieved from https://www.cpcscientific.com/ [4] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP) Information. Retrieved from https://www.fda.gov/ [5] European Medicines Agency. (n.d.). Good Manufacturing Practice. Retrieved from https://www.ema.europa.eu/